Skip to main
ICUI

ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical (ICUI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ICU Medical is well-positioned in the US market, which accounts for over 60% of its sales. It has a diverse portfolio with strong revenue streams from consumables, infusion systems, and vital care. Despite some potential risks, the company's recent acquisitions of Hospira Infusion Systems and Smiths Medical have solidified its position as a top player in the infusion therapy industry and could lead to further growth and expansion opportunities.

Bears say

ICU Medical is facing challenges related to its recent acquisitions, with a large portion of its revenue coming from the U.S. market and a significant portion of its products running on separate platforms, causing inefficiencies and a disadvantage in the market. Additionally, rising oil prices and a strengthening Mexican peso are pressuring the company's costs, and an outstanding FDA warning letter could delay product approvals and add regulatory risks. Lastly, the company's exposure to oil prices and tariffs, along with a decrease in free cash flow, may limit its ability to conduct share repurchases for EPS growth.

ICU Medical (ICUI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICU Medical (ICUI) Forecast

Analysts have given ICU Medical (ICUI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, ICU Medical (ICUI) has a Strong Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $172, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $172, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICU Medical (ICUI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.